Claims for Patent: 10,258,639

Summary for Patent: 10,258,639

Title:	Methods for treating insulin resistance and for sensitizing patients to GLP1 agonist therapy
Abstract:	Methods for treatment of insulin resistance and type II diabetes by administration of inhibitors of the PKI pathway are provided. In some aspects, inhibitors of the PKI pathway, such as inhibitors of PIKB, HIF1 and/or mTOR, can be used to treat subject having insulin resistance who are refractory to GLP1 agonist therapy.
Inventor(s):	Montminy; Marc (La Jolla, CA), Van De Velde; Sam (La Jolla, CA), Blanchet; Emilie (La Jolla, CA)
Assignee:	Research Development Foundation (Carson City, NV)
Application Number:	15/308,652
Patent Claims:	1. A method for treating a diabetic subject resistant to a Glucagon-like peptide-1 (GLP1) agonist therapy comprising administering an effective amount of a PKIB pathway inhibitor to the subject, wherein the PKIB pathway inhibitor is selected from the group consisting of an inhibitor of PKIB, a mTOR inhibitor and a HIF inhibitor. 2. The method of claim 1, wherein the subject has been diagnosed with Type II Diabetes. 3. The method of claim 1, wherein the subject is resistant to Exenatide, Liraglutide, Taspoglutide, Albiglutide and/or Lixisenatide. 4. The method of claim 1, wherein the subject is a human subject. 5. The method of claim 1, further comprising administering to the subject a GLP1 agonist. 6. The method of claim 1, wherein the PKIB pathway inhibitor is a mTOR inhibitor. 7. The method of claim 6, wherein the mTOR inhibitor is sirolimus, everolimus, temsirolimus, or rapamycin. 8. The method of claim 1, wherein the PKIB pathway inhibitor is an inhibitor of PKIB. 9. The method of claim 8, wherein the inhibitor of PKIB is an inhibitory nucleic acid. 10. The method of claim 9, wherein the inhibitory nucleic acid is a complementary to all or part of the sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7or SEQ ID NO: 8. 11. The method of claim 9, wherein the inhibitory nucleic acid is a siRNA or dsRNA. 12. The method of claim 1, wherein the PKIB pathway inhibitor is a HIF inhibitor. 13. The method of claim 1, wherein the HIF inhibitor is FG-4592, IOX2, 2-Methoxyestradiol (2-MeOE2), CL67, CAY10585 (CAS 934593-90-5), sc-205346 (CAS 934593-90-5), Chetomin (CAS 1403-36-7) or Chrysin (CAS 480-40-0). 14. The method of claim 1, wherein the subject has been determined to be resistant to the Glucagon-like peptide-1 (GLP1) agonist therapy. 15. The method of claim 5, wherein the GLP1 agonist is Exenatide, Liraglutide, Taspoglutide, Albiglutide or Lixisenatide.

Details for Patent 10,258,639

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431	April 15, 2014		2035-05-06
Sanofi-aventis U.s. Llc	ADLYXIN	lixisenatide	Injection	208471	July 27, 2016		2035-05-06